Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer
Background A retrospective study was conducted to assess the efficacy and toxicity of lobaplatin‐etoposide (EL) chemotherapy for small cell lung cancer (SCLC). Methods The clinical data of 50 patients treated in our department from May 2014 to March 2018 were obtained. Untreated patients with SCLC a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.12936 |
| _version_ | 1819077466180812800 |
|---|---|
| author | Liyan Gu Diansheng Zhong Tao Yu Ping Tang Fanlu Meng Qiong Qin |
| author_facet | Liyan Gu Diansheng Zhong Tao Yu Ping Tang Fanlu Meng Qiong Qin |
| author_sort | Liyan Gu |
| collection | DOAJ |
| description | Background A retrospective study was conducted to assess the efficacy and toxicity of lobaplatin‐etoposide (EL) chemotherapy for small cell lung cancer (SCLC). Methods The clinical data of 50 patients treated in our department from May 2014 to March 2018 were obtained. Untreated patients with SCLC administered LBP intravenously (IV) at 30 mg/m2 on day 1 and etoposide IV at 100 mg/m2 on days 1, 2, and 3 were enrolled. The treatment was cycled every 21 days. Results The median overall and progression‐free survival rates of the 50 patients were 11.67 (range: 7.30–16.04) and 6.8 (range: 5.25–8.35) months, respectively, with an overall response rate of 66% and a disease control rate of 90%. The most frequent drug‐related adverse effects were leukopenia and neutropenia, and no grade 3/4 hepatotoxicity or nephrotoxicity was observed. Conclusion These results indicate that LBP‐containing chemotherapy is effective and tolerable for SCLC in terms of response and survival. |
| first_indexed | 2024-12-21T18:57:39Z |
| format | Article |
| id | doaj.art-d5fd0f568b8e4a3baf4387ef6f7cc7cb |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-12-21T18:57:39Z |
| publishDate | 2019-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-d5fd0f568b8e4a3baf4387ef6f7cc7cb2022-12-21T18:53:34ZengWileyThoracic Cancer1759-77061759-77142019-02-0110222623310.1111/1759-7714.12936Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancerLiyan Gu0Diansheng Zhong1Tao Yu2Ping Tang3Fanlu Meng4Qiong Qin5Department of Oncology Tianjin Medical University General Hospital Tianjin ChinaDepartment of Oncology Tianjin Medical University General Hospital Tianjin ChinaDepartment of Oncology Tianjin Medical University General Hospital Tianjin ChinaDepartment of Oncology Tianjin Medical University General Hospital Tianjin ChinaDepartment of Oncology Tianjin Medical University General Hospital Tianjin ChinaDepartment of Oncology Tianjin Medical University General Hospital Tianjin ChinaBackground A retrospective study was conducted to assess the efficacy and toxicity of lobaplatin‐etoposide (EL) chemotherapy for small cell lung cancer (SCLC). Methods The clinical data of 50 patients treated in our department from May 2014 to March 2018 were obtained. Untreated patients with SCLC administered LBP intravenously (IV) at 30 mg/m2 on day 1 and etoposide IV at 100 mg/m2 on days 1, 2, and 3 were enrolled. The treatment was cycled every 21 days. Results The median overall and progression‐free survival rates of the 50 patients were 11.67 (range: 7.30–16.04) and 6.8 (range: 5.25–8.35) months, respectively, with an overall response rate of 66% and a disease control rate of 90%. The most frequent drug‐related adverse effects were leukopenia and neutropenia, and no grade 3/4 hepatotoxicity or nephrotoxicity was observed. Conclusion These results indicate that LBP‐containing chemotherapy is effective and tolerable for SCLC in terms of response and survival.https://doi.org/10.1111/1759-7714.12936Chemotherapylobaplatinsmall cell lung cancer |
| spellingShingle | Liyan Gu Diansheng Zhong Tao Yu Ping Tang Fanlu Meng Qiong Qin Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer Thoracic Cancer Chemotherapy lobaplatin small cell lung cancer |
| title | Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer |
| title_full | Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer |
| title_fullStr | Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer |
| title_full_unstemmed | Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer |
| title_short | Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer |
| title_sort | retrospective study of the efficacy and toxicity of lobaplatin etoposide chemotherapy in small cell lung cancer |
| topic | Chemotherapy lobaplatin small cell lung cancer |
| url | https://doi.org/10.1111/1759-7714.12936 |
| work_keys_str_mv | AT liyangu retrospectivestudyoftheefficacyandtoxicityoflobaplatinetoposidechemotherapyinsmallcelllungcancer AT dianshengzhong retrospectivestudyoftheefficacyandtoxicityoflobaplatinetoposidechemotherapyinsmallcelllungcancer AT taoyu retrospectivestudyoftheefficacyandtoxicityoflobaplatinetoposidechemotherapyinsmallcelllungcancer AT pingtang retrospectivestudyoftheefficacyandtoxicityoflobaplatinetoposidechemotherapyinsmallcelllungcancer AT fanlumeng retrospectivestudyoftheefficacyandtoxicityoflobaplatinetoposidechemotherapyinsmallcelllungcancer AT qiongqin retrospectivestudyoftheefficacyandtoxicityoflobaplatinetoposidechemotherapyinsmallcelllungcancer |